BRPI0712195A2 - composição farmacéutica, e, usos da composição e de um inibidor de reabsorção da serotonina ou um sal farmaceuticamente aceitável do mesmo e de 5-hidroxitriptofano - Google Patents

composição farmacéutica, e, usos da composição e de um inibidor de reabsorção da serotonina ou um sal farmaceuticamente aceitável do mesmo e de 5-hidroxitriptofano Download PDF

Info

Publication number: BRPI0712195A2
Authority: BR; Brazil
Prior art keywords: hydroxytryptophan; administered; amount; pharmaceutically acceptable; acceptable salt
Prior art date: 2007-05-11

Application number

BRPI0712195-4A

Other languages

English (en)

Portuguese (pt)

Inventor

Connie Sanchez Morillo

Toni D Wolinsky

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-11

Filing date

2007-05-11

Publication date

2012-01-10

2007-05-11 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2012-01-10 Publication of BRPI0712195A2 publication Critical patent/BRPI0712195A2/pt

Links

229940000681 5-hydroxytryptophan Drugs 0.000 title claims abstract description 155
LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 title claims abstract description 154
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 title claims abstract description 153
239000003772 serotonin uptake inhibitor Substances 0.000 title claims abstract description 110
229940126570 serotonin reuptake inhibitor Drugs 0.000 title claims abstract description 91
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 79
239000000203 mixture Substances 0.000 title claims abstract description 54
150000003839 salts Chemical class 0.000 title claims abstract description 33
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 80
229940076279 serotonin Drugs 0.000 claims abstract description 38
239000003112 inhibitor Substances 0.000 claims abstract description 21
229960004341 escitalopram Drugs 0.000 claims description 71
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 70
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 48
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 46
229960002296 paroxetine Drugs 0.000 claims description 46
-1 serotonin compound Chemical class 0.000 claims description 22
239000002552 dosage form Substances 0.000 claims description 17
238000006114 decarboxylation reaction Methods 0.000 claims description 14
230000002093 peripheral effect Effects 0.000 claims description 14
239000002775 capsule Substances 0.000 claims description 13
208000019901 Anxiety disease Diseases 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 10
229960004205 carbidopa Drugs 0.000 claims description 8
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 8
208000019022 Mood disease Diseases 0.000 claims description 5
230000036506 anxiety Effects 0.000 claims description 4
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical group NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 4
238000002648 combination therapy Methods 0.000 abstract description 14
230000009103 reabsorption Effects 0.000 abstract description 3
150000001875 compounds Chemical class 0.000 description 43
230000027455 binding Effects 0.000 description 31
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 26
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 26
238000012360 testing method Methods 0.000 description 25
230000000694 effects Effects 0.000 description 21
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 16
229940125516 allosteric modulator Drugs 0.000 description 16
230000001225 therapeutic effect Effects 0.000 description 16
229960002464 fluoxetine Drugs 0.000 description 15
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 14
230000003281 allosteric effect Effects 0.000 description 14
229960001653 citalopram Drugs 0.000 description 14
230000009102 absorption Effects 0.000 description 12
238000010521 absorption reaction Methods 0.000 description 12
238000010494 dissociation reaction Methods 0.000 description 12
230000005593 dissociations Effects 0.000 description 12
239000003826 tablet Substances 0.000 description 12
238000000034 method Methods 0.000 description 11
239000002287 radioligand Substances 0.000 description 10
229960002073 sertraline Drugs 0.000 description 10
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 10
238000009097 single-agent therapy Methods 0.000 description 10
241000700159 Rattus Species 0.000 description 8
230000008901 benefit Effects 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
238000012048 forced swim test Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
239000002585 base Substances 0.000 description 7
239000000872 buffer Substances 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 7
229960004038 fluvoxamine Drugs 0.000 description 7
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 7
230000036470 plasma concentration Effects 0.000 description 7
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 6
229960002866 duloxetine Drugs 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
238000001690 micro-dialysis Methods 0.000 description 6
239000000523 sample Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 5
229960004801 imipramine Drugs 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000006186 oral dosage form Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 5
229960004688 venlafaxine Drugs 0.000 description 5
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 4
229960004606 clomipramine Drugs 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 4
229950003930 femoxetine Drugs 0.000 description 4
238000011534 incubation Methods 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
239000003446 ligand Substances 0.000 description 4
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 4
229960001800 nefazodone Drugs 0.000 description 4
239000000725 suspension Substances 0.000 description 4
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 description 3
229960005217 dapoxetine Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000012552 review Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XFPJZGUGGRESHD-PHJLCXHGSA-N (6r,10br)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline;hydrobromide Chemical compound Br.ClC1=CC=CC=C1[C@H]1C2=CC=CC=C2[C@H]2CCCN2C1 XFPJZGUGGRESHD-PHJLCXHGSA-N 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229960000836 amitriptyline Drugs 0.000 description 2
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
230000003416 augmentation Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000011278 co-treatment Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
210000005153 frontal cortex Anatomy 0.000 description 2
230000003993 interaction Effects 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
FTKXWCQSVJPWPZ-VDWBQBBKSA-N org 6906 Chemical compound Cl.C1C2=CC=CC=C2[C@H]2C=C[C@@H](N)[C@@H]1C2 FTKXWCQSVJPWPZ-VDWBQBBKSA-N 0.000 description 2
AVVSOBGTJTTZKQ-RXVWUEJASA-N org 6997 Chemical compound Cl.C1C2=CC(Cl)=CC=C2[C@H]2C=C[C@@H](N)[C@@H]1C2 AVVSOBGTJTTZKQ-RXVWUEJASA-N 0.000 description 2
LWRJZIPAGMGXQJ-DIJVWCDGSA-N org-6582 Chemical compound Cl.C1C2=CC(Cl)=CC=C2[C@@H]2[C@@H](N)[C@H]1C=CC2 LWRJZIPAGMGXQJ-DIJVWCDGSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
210000003568 synaptosome Anatomy 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000003151 transfection method Methods 0.000 description 2
KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical group OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
NRNSHPCDKHOUOE-SNVBAGLBSA-N (2s)-2-amino-2-[(3,4-dihydroxyphenyl)methyl]-3-fluoropropanoic acid Chemical compound FC[C@@](N)(C(O)=O)CC1=CC=C(O)C(O)=C1 NRNSHPCDKHOUOE-SNVBAGLBSA-N 0.000 description 1
WIQRCHMSJFFONW-HNNXBMFYSA-N (3s)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound O([C@@H](CCN)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-HNNXBMFYSA-N 0.000 description 1
YVKDUIAAPBKHMJ-MOPGFXCFSA-N (6R,10bS)-6-[4-(methylthio)phenyl]-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinoline Chemical compound C1=CC(SC)=CC=C1[C@@H]1C2=CC=CC=C2[C@@H]2CCCN2C1 YVKDUIAAPBKHMJ-MOPGFXCFSA-N 0.000 description 1
STDYWHYUOSSCBO-UHFFFAOYSA-N 2,3-dimethyl-4-phenyl-4,5-dihydro-1,3-benzodiazepine Chemical compound C1C2=CC=CC=C2N=C(C)N(C)C1C1=CC=CC=C1 STDYWHYUOSSCBO-UHFFFAOYSA-N 0.000 description 1
WETRBJOSGIDJHQ-UHFFFAOYSA-N 2-(3,4-dihydronaphthalen-2-ylmethyl)-4,5-dihydro-1h-imidazole Chemical compound C=1C2=CC=CC=C2CCC=1CC1=NCCN1 WETRBJOSGIDJHQ-UHFFFAOYSA-N 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
FWYRGHMKHZXXQX-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol Chemical compound CN(C)C(C)(CO)CC1=CC=C(Cl)C(Cl)=C1 FWYRGHMKHZXXQX-UHFFFAOYSA-N 0.000 description 1
NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-SECBINFHSA-N 5-hydroxy-D-tryptophan Chemical compound C1=C(O)C=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-SECBINFHSA-N 0.000 description 1
150000004803 5-hydroxytryptophans Chemical class 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241001631457 Cannula Species 0.000 description 1
102000004031 Carboxy-Lyases Human genes 0.000 description 1
108090000489 Carboxy-Lyases Proteins 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
206010014952 Eosinophilia myalgia syndrome Diseases 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101000631929 Homo sapiens Sodium-dependent serotonin transporter Proteins 0.000 description 1
206010021030 Hypomania Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000030990 Impulse-control disease Diseases 0.000 description 1
KSMITTDZTTZFML-LURJTMIESA-N Jasminine Chemical compound C[C@@H]1NC(=O)CC2=C1C=NC=C2C(=O)OC KSMITTDZTTZFML-LURJTMIESA-N 0.000 description 1
IWVRVEIKCBFZNF-UHFFFAOYSA-N LSM-1636 Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
FZSPJBYOKQPKCD-VIFPVBQESA-N [1-(4-chlorophenyl)-2-methylpropan-2-yl] (2s)-2-aminopropanoate Chemical compound C[C@H](N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-VIFPVBQESA-N 0.000 description 1
QICQDZXGZOVTEF-UHFFFAOYSA-N [3-(3,4-dichlorophenyl)-2,3-dihydro-1h-inden-1-yl]-methylazanium;chloride Chemical compound Cl.C12=CC=CC=C2C(NC)CC1C1=CC=C(Cl)C(Cl)=C1 QICQDZXGZOVTEF-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000026345 acute stress disease Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
229960003225 alaproclate Drugs 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000008856 allosteric binding Effects 0.000 description 1
CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960002519 amoxapine Drugs 0.000 description 1
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000002539 anti-aggressive effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
229960000911 benserazide Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
229950000303 cericlamine Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229950002663 clovoxamine Drugs 0.000 description 1
XXPVSQRPGBUFKM-SAPNQHFASA-N clovoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(Cl)C=C1 XXPVSQRPGBUFKM-SAPNQHFASA-N 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
229950005551 dazepinil Drugs 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
150000001993 dienes Chemical class 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229940083607 fluoxetine 10 mg Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000004459 forage Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
102000055801 human SLC6A4 Human genes 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
ZHFIAFNZGWCLHU-YPMHNXCESA-N ifoxetine Chemical compound CC1=CC=CC(O[C@@H]2[C@@H](CNCC2)O)=C1C ZHFIAFNZGWCLHU-YPMHNXCESA-N 0.000 description 1
229950006314 ifoxetine Drugs 0.000 description 1
229960003441 imipramine oxide Drugs 0.000 description 1
QZIQORUGXBPDSU-UHFFFAOYSA-N imipramine oxide Chemical compound C1CC2=CC=CC=C2N(CCC[N+](C)([O-])C)C2=CC=CC=C21 QZIQORUGXBPDSU-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000011872 intimate mixture Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
229950000323 napamezole Drugs 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229960000751 nefopam Drugs 0.000 description 1
229960003057 nialamide Drugs 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
229950001527 nitroxazepine Drugs 0.000 description 1
CGYWLLGTCBIGSR-UHFFFAOYSA-N nitroxazepine Chemical compound O=C1N(CCCN(C)C)C2=CC=CC=C2OC2=CC=C([N+]([O-])=O)C=C21 CGYWLLGTCBIGSR-UHFFFAOYSA-N 0.000 description 1
229960001158 nortriptyline Drugs 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229960002888 oxitriptan Drugs 0.000 description 1
230000009057 passive transport Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
208000019899 phobic disease Diseases 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229950007239 pirandamine Drugs 0.000 description 1
AMJPIGOYWBNJLP-UHFFFAOYSA-N pirandamine Chemical compound C1C2=CC=CC=C2C2=C1C(CCN(C)C)(C)OCC2 AMJPIGOYWBNJLP-UHFFFAOYSA-N 0.000 description 1
229950002220 pirlindole Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229940126027 positive allosteric modulator Drugs 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229940124811 psychiatric drug Drugs 0.000 description 1
229960000279 quinupramine Drugs 0.000 description 1
JCBQCKFFSPGEDY-UHFFFAOYSA-N quinupramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
229950000319 seproxetine Drugs 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
229960003740 vilazodone Drugs 0.000 description 1
SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
XZVHHLNLLVICFA-SNVBAGLBSA-N α-difluoromethyl-dopa Chemical compound FC(F)[C@](C(O)=O)(N)CC1=CC=C(O)C(O)=C1 XZVHHLNLLVICFA-SNVBAGLBSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0712195-4A 2007-05-11 2007-05-11 composição farmacéutica, e, usos da composição e de um inibidor de reabsorção da serotonina ou um sal farmaceuticamente aceitável do mesmo e de 5-hidroxitriptofano BRPI0712195A2 (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2007/011362 WO2008140448A1 (en)	2007-05-11	2007-05-11	5-htp combination therapy

Publications (1)

Publication Number	Publication Date
BRPI0712195A2 true BRPI0712195A2 (pt)	2012-01-10

Family

ID=40002488

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0712195-4A BRPI0712195A2 (pt)	2007-05-11	2007-05-11	composição farmacéutica, e, usos da composição e de um inibidor de reabsorção da serotonina ou um sal farmaceuticamente aceitável do mesmo e de 5-hidroxitriptofano

Country Status (11)

Country	Link
EP (1)	EP2155181A4 (de)
JP (1)	JP2010526804A (de)
KR (1)	KR20100014081A (de)
CN (1)	CN101472575A (de)
AU (1)	AU2007353453A1 (de)
BR (1)	BRPI0712195A2 (de)
CA (1)	CA2655846A1 (de)
EA (1)	EA200870554A1 (de)
IL (1)	IL196041A0 (de)
NO (1)	NO20085278L (de)
WO (1)	WO2008140448A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11464756B1 (en)	2017-05-19	2022-10-11	Jerry Darm	Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6579899B1 (en) *	1998-07-16	2003-06-17	Massachusetts Institute Of Technology	Composition for treatment of stress

2007
- 2007-05-11 CN CNA2007800229678A patent/CN101472575A/zh active Pending
- 2007-05-11 BR BRPI0712195-4A patent/BRPI0712195A2/pt not_active IP Right Cessation
- 2007-05-11 EP EP07776982A patent/EP2155181A4/de not_active Withdrawn
- 2007-05-11 EA EA200870554A patent/EA200870554A1/ru unknown
- 2007-05-11 WO PCT/US2007/011362 patent/WO2008140448A1/en not_active Ceased
- 2007-05-11 AU AU2007353453A patent/AU2007353453A1/en not_active Abandoned
- 2007-05-11 KR KR1020087030898A patent/KR20100014081A/ko not_active Withdrawn
- 2007-05-11 CA CA002655846A patent/CA2655846A1/en not_active Abandoned
- 2007-05-11 JP JP2010507368A patent/JP2010526804A/ja active Pending
2008
- 2008-12-18 IL IL196041A patent/IL196041A0/en unknown
- 2008-12-18 NO NO20085278A patent/NO20085278L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2010526804A (ja)	2010-08-05
AU2007353453A1 (en)	2008-11-20
CA2655846A1 (en)	2008-11-20
EP2155181A1 (de)	2010-02-24
KR20100014081A (ko)	2010-02-10
EA200870554A1 (ru)	2009-04-28
NO20085278L (no)	2009-02-12
WO2008140448A1 (en)	2008-11-20
CN101472575A (zh)	2009-07-01
EP2155181A4 (de)	2012-02-29
IL196041A0 (en)	2009-09-01

Legal Events

Date	Code	Title	Description
2012-06-05	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A E 5A ANUIDADES.
2012-11-13	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 4A E 5A ANUIDADES.

Publication	Publication Date	Title
US20120258984A1 (en)	2012-10-11	5-htp combination therapy
US20100267772A1 (en)	2010-10-21	Combination of a Serotonin Reuptake Inhibitor and Agomelatine
WO2001041766A1 (en)	2001-06-14	The combination of a serotonin reuptake inhibitor and irindalone
TW200843763A (en)	2008-11-16	5-HTP combination therapy
US20020107244A1 (en)	2002-08-08	Combination treatment for depression
EP2145620A2 (de)	2010-01-20	Gaboxadol zur Behandlung von Depression und anderer affektiver Störungen
AU2003240434A1 (en)	2004-01-06	Combination therapy wherein a serotinin reuptake inhibitor is used
WO2009042632A2 (en)	2009-04-02	Combination therapy related to serotonin dual action compounds
BRPI0712195A2 (pt)	2012-01-10	composição farmacéutica, e, usos da composição e de um inibidor de reabsorção da serotonina ou um sal farmaceuticamente aceitável do mesmo e de 5-hidroxitriptofano
CA2537747A1 (en)	2005-03-17	The combination of a serotonin reuptake inhibitor and loxapine
US20070042014A1 (en)	2007-02-22	Combination of a serotonin reuptake inhibitor and loxapine
WO2005056056A2 (en)	2005-06-23	The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US20070066601A1 (en)	2007-03-22	Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
HK1134241A (en)	2010-04-23	5-htp combination therapy
MX2008016138A (es)	2009-05-13	Terapia de combinacion de 5-htp
EP1660130A1 (de)	2006-05-31	Kombination eines serotonin-wiederaufnahmehemmers mit einem glycin transporter typ 1 hemmer zur behandlung von depressionen
US20080167290A1 (en)	2008-07-10	Combination of a Serotonin Reuptake Inhibitor and Amoxapine
CA2537757A1 (en)	2005-03-17	The combination of a serotonin reuptake inhibitor and amoxapine